These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 8539331

  • 1. Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist.
    Damaj MI, Creasy KR, Welch SP, Rosecrans JA, Aceto MD, Martin BR.
    Psychopharmacology (Berl); 1995 Aug; 120(4):483-90. PubMed ID: 8539331
    [Abstract] [Full Text] [Related]

  • 2. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS.
    J Pharmacol Exp Ther; 1994 Jul; 270(1):310-8. PubMed ID: 7518514
    [Abstract] [Full Text] [Related]

  • 3. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT.
    J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
    [Abstract] [Full Text] [Related]

  • 4. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
    Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J.
    Alzheimer Dis Assoc Disord; 1995 Jul; 9 Suppl 2():50-61. PubMed ID: 8534424
    [Abstract] [Full Text] [Related]

  • 5. ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity.
    Brioni JD, Kim DJ, Brodie MS, Decker MW, Arneric SP.
    Psychopharmacology (Berl); 1995 Jun; 119(4):368-75. PubMed ID: 7480515
    [Abstract] [Full Text] [Related]

  • 6. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418.
    Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP.
    J Pharmacol Exp Ther; 1994 Oct; 271(1):353-61. PubMed ID: 7965735
    [Abstract] [Full Text] [Related]

  • 7. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement.
    Buccafusco JJ, Jackson WJ, Terry AV, Marsh KC, Decker MW, Arneric SP.
    Psychopharmacology (Berl); 1995 Aug; 120(3):256-66. PubMed ID: 8524972
    [Abstract] [Full Text] [Related]

  • 8. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys.
    Prendergast MA, Jackson WJ, Terry AV, Decker MW, Arneric SP, Buccafusco JJ.
    Psychopharmacology (Berl); 1998 Mar; 136(1):50-8. PubMed ID: 9537682
    [Abstract] [Full Text] [Related]

  • 9. Characterization of [3H]ABT-418: a novel cholinergic channel ligand.
    Anderson DJ, Williams M, Pauly JR, Raszkiewicz JL, Campbell JE, Rotert G, Surber B, Thomas SB, Wasicak J, Arneric SP.
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1434-41. PubMed ID: 7791118
    [Abstract] [Full Text] [Related]

  • 10. Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.
    Turchi J, Holley LA, Sarter M.
    Psychopharmacology (Berl); 1995 Mar; 118(2):195-205. PubMed ID: 7617808
    [Abstract] [Full Text] [Related]

  • 11. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains.
    Warpman U, Nordberg A.
    Neuroreport; 1995 Nov 27; 6(17):2419-23. PubMed ID: 8747166
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and nicotinic activity of epiboxidine: an isoxazole analogue of epibatidine.
    Badio B, Garraffo HM, Plummer CV, Padgett WL, Daly JW.
    Eur J Pharmacol; 1997 Feb 26; 321(2):189-94. PubMed ID: 9063687
    [Abstract] [Full Text] [Related]

  • 13. In vitro evaluation of 11C-labeled (S)-nicotine, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (R,S)-1-methyl-2-(3-pyridyl)azetidine as nicotinic receptor ligands for positron emission tomography studies.
    Sihver W, Fasth KJ, Ogren M, Bivehed H, Bergström M, Nordberg A, Watanabe Y, Långström B.
    J Neurochem; 1998 Oct 26; 71(4):1750-60. PubMed ID: 9751211
    [Abstract] [Full Text] [Related]

  • 14. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
    Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1998 May 26; 285(2):777-86. PubMed ID: 9580626
    [Abstract] [Full Text] [Related]

  • 15. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
    Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1997 Oct 26; 283(1):235-46. PubMed ID: 9336329
    [Abstract] [Full Text] [Related]

  • 16. Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models.
    Stevens KE, Wear KD.
    Pharmacol Biochem Behav; 1997 Aug 26; 57(4):869-74. PubMed ID: 9259018
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological investigation of (+)- and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo-[3,2-h]isoq uinoline, a bridged-nicotine analog.
    Damaj MI, Glassco W, Marks MJ, Slobe B, James JR, May EL, Rosecrans JA, Collins AC, Martin BR.
    J Pharmacol Exp Ther; 1997 Sep 26; 282(3):1425-34. PubMed ID: 9316856
    [Abstract] [Full Text] [Related]

  • 18. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors.
    Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F.
    Neuropsychopharmacology; 2003 Jul 26; 28(7):1235-46. PubMed ID: 12700710
    [Abstract] [Full Text] [Related]

  • 19. A study of the nicotinic agonist SIB-1553A on locomotion and attention as measured by the five-choice serial reaction time task.
    Grottick AJ, Wyler R, Higgins GA.
    Pharmacol Biochem Behav; 2001 Dec 26; 70(4):505-13. PubMed ID: 11796150
    [Abstract] [Full Text] [Related]

  • 20. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist.
    Damaj MI, Glassco W, Aceto MD, Martin BR.
    J Pharmacol Exp Ther; 1999 Oct 26; 291(1):390-8. PubMed ID: 10490929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.